Teva Pharmaceutical (NYSE:TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 on Wednesday. The company lost over 20% in the preceding six sessions.
Teva Pharmaceutical Industries Limited has a 12-month low of $11.83 and a 12-month high of $22.80. The stock has a market capitalization of $19.07 billion, a PE ratio of -11.61, a price-to ...
Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.
Try Now>> See today’s best-performing stocks on TipRanks >> Read More on TEVA: Teva Pharmaceutical Industries NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Evercore ISI analyst Umer Raffat maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) on January 31. The company’s shares ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report)’s share price was down 4.6% on Thursday after UBS Group lowered their price target on the stock from $30.00 to $27.00.
Teva Pharmaceutical Industries ( NYSE:TEVA ) Full Year 2024 Results Key Financial Results Revenue: US$16.5b (up 4.4... This pharma stock has made strong gains over the past 12 months thanks to its ...
Axsome Therapeutics has resolved the patent infringement lawsuit that it filed against Teva Pharmaceutical Industries after the generics powerhouse sought FDA approval for a copycat to Axsome's ...
Below is Validea's guru fundamental report for TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR) (TEVA). Of the 22 guru strategies we follow, TEVA rates highest using our Acquirer's Multiple Investor model ...
Axsome Therapeutics shares were up 14% in premarket trading after reaching a settlement with Teva Pharmaceuticals. Shares were trading around $120.01. The stock is up 8.3% over the last year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results